Term ended Jul 18, 2026 · High confidence
20-year base term ended Nov 22, 2025
Held by Adamas Pharmaceuticals, Inc.
Filed Jul 30, 2009 as application 12/512,701 · Granted May 1, 2012
Base term plus 238 days of patent term adjustment (USPTO delay)
Today
Term ended Jul 18, 2026
2005
2026
Clock starts
Nov 22, 2005
Nov 22, 2005
Term ended
Jul 18, 2026
Jul 18, 2026
Granted
May 1, 2012
May 1, 2012
base term
patent term adjustment
after the term ends
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
238
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
No effect
Terminal disclaimer
Resolved from the filed document, referencing US 8,058,291, to Jul 18, 2026. The term already ends on or before that date, so the cap shortened nothing.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
43
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term runs 238 days past its 20-year base term on prosecution delay. A terminal disclaimer is resolved from the filed document, and it ends no earlier than this term, so it shortens nothing. All three maintenance fees were paid, so no fee lapse ended it. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 22, 2005, when application 11/285,905, the earliest non-provisional in its chain, was filed (this one was filed Jul 30, 2009) | Nov 22, 2025 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +238 days, USPTO patent term adjustment record | Jul 18, 2026 | High confidence |
| Terminal disclaimer cap | Disclaimer resolved from the filed document (refs US 8,058,291) | resolves to Jul 18, 2026, no earlier than this term, so no change | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | term ended | High confidence |
| Computed term end | The steps above, in order | Jul 18, 2026 | High confidence |
This family
| US 6,620,845 | Lapsed on the fee record Sep 2015 | Sep 2015 |
| Application 60/630,885 | Provisional application no patent term | no patent term |
| US 7,326,730 | Term ended Feb 2020 | Feb 2020 |
| US 7,619,007 | Term ended no later than Nov 2025 | no later than Nov 2025 |
| US 8,058,291 | In force Dec 2029 | Dec 2029 |
| Application PCT/US2006/013506 | PCT application no patent term | no patent term |
| Application PCT/US2007/011887 | PCT application no patent term | no patent term |
| US 8,168,209 | this patent Jul 2026 | Jul 2026 |
8 of 43 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jan 23, 2012 Reel 27575, frame 880 | Went, Gregory T.; Fultz, Timothy J.; Porter, Seth; Meyerson, Laurence R.; Burkoth, Timothy S. | Neuromolecular, Inc. | Assignment of Assignor's Interest |
| Jan 23, 2012 Reel 27576, frame 495 | Neuromolecular Pharmaceuticals, Inc. | Adamas Pharmaceuticals, Inc. | Change of Name |
| Jan 29, 2014 Reel 32136, frame 297 | Neuromolecular, Inc. | Neuromolecular Pharmaceuticals, Inc. | Change of Name |
| Jun 6, 2017 Reel 42704, frame 254 | Adamas Pharmaceuticals, Inc. | Adamas Pharma, LLC | Assignment of Assignor's Interest |
| Nov 29, 2017 Reel 44548, frame 480 | Neuromolecular Pharmaceuticals, Inc. | Adamas Pharmaceuticals, Inc. | Change of Name |
| Dec 19, 2017 Reel 44441, frame 683 | Went, Gregory T.; Fultz, Timothy J. | Neuromolecular Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Dec 19, 2017 Reel 44441, frame 698 | Meyerson, Laurence R. | Adamas Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Dec 26, 2017 Reel 44483, frame 977 | Went, Gregory T.; Fultz, Timothy J.; Porter, Seth; Meyerson, Laurence R.; Burkoth, Timothy S. | Adamas Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
What's changing
Note
The 238 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Terminal disclaimer
A terminal disclaimer resolved from the filed document, referencing US 8,058,291, ends no earlier than this term, so it caps nothing.
Citations
57
later US patents cite this one
That is top 25% of utility patents granted in 2012 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.